作者：
Liu, Maggie [1]
;
Fields, F. Owen [2]
;
Prescott, Judith S. [3]
;
Bello, Akintunde [4]
;
Bower, Nancy [5]
;
Darakjy, Salima [6]
;
Hartke, James [7]
;
Kadambi, Vivek [8]
;
Lapadula, Daniel [9]
;
Stoch, Aubrey [10]
;
Derzi, Mazin [11]
作者单位：
Bristol Myers Squibb, Clin Pharmacol & Pharmacometr, Princeton, NJ USA
[1]
Worldwide Global Regulatory Affairs, Collegeville, PA USA
[2]
Celgene, Nonclin Dev, La Jolla, CA USA
[3]
Pfizer Inc, Drug Safety Res & Dev, Cambridge, MA USA
[4]
Pfizer Inc, Drug Safety Res & Dev, La Jolla, CA 92121 USA
[5]
Merck & Co Inc, Safety Assessment & Lab Anim Resources, West Point, PA USA
[6]
Eisai Inc, Global Nonclin Regulatory, Woodcliff Lake, NJ USA
[7]
Pfizer Inc, Worldwide Med & Safety, New York, NY USA
[8]
Merck & Co Inc, Translat Pharmacol, Kenilworth, NJ USA
[9]
Blueprint Med, Quantitat Pharmacol & Drug Safety Evaluat, Cambridge, MA USA
[10]
Novartis Inst Biomed Res, Preclin Safety, E Hanover, NJ USA
[11]
发布时间
2020-10-22
换一批
